59 drug samples including Cadila Pharma Aciloc 150 fail to qualify CDSCO test

In its latest drug safety alert, the apex drug regulatory body, Central Drugs Standard Control Organization (CDSCO) has flagged 59 medicine batches for failing to qualify a random drug sample test for the month of September, 2022.

This came in line with the list of drugs, medical devices and cosmetics declared as Not of Standard Quality/Spurious/Adulterated/Misbranded for the Month of September, 2022.

These drug samples which are declared not of standard quality include Paracetamol Tablets IP 650 mg, Ascorbic Acid Tablets IP 500 mg manufactured by ANG Lifesciences India, Montelukast Sodium and Levocetirizine Dihydrochloride Tablets IP (Viznil) manufactured by Tirupati Medicare Limited, Atorvastatin Tablets IP 20 mg manufactured by Galpha Laboratories, Azithromycin Tablets IP 500mg AZUSTAN-500 Tablets manufactured by Mediwell Biotech and others.

For more details, check out the link given below:

59 Drug Samples Including Cadila Pharma Aciloc 150 Fail To Qualify CDSCO Test